Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05659615
Other study ID # 44382120.3.0000.5208
Secondary ID 4.666.483
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date February 10, 2023

Study information

Verified date December 2022
Source University of Pernambuco
Contact Shiley L Campos, PhD
Phone +55 (81) 2126-8492
Email shirley.campos@ufpe.br
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The COVID-19 pandemic, a disease caused by the SARS-CoV-2 virus, has generated an inexplicable scenario for global health, causing different complications and degrees of functional impairment in millions of people who manage to recover from the disease. The respiratory system is the main system to be directly impacted during COVID-19 infection, and its treatment can generate changes in the respiratory function of individuals surviving the exacerbation of the disease, which may promote subjective and quantitative changes in the respiratory pattern, requiring an evaluation with high-cost instruments, an evaluation necessary to outline a better planning therapeutic for this population. The goal of this study is evaluate the breathing pattern variables using a device called RESPIRATORY DIAGNOSTIC ASSISTANT (RDA) and verify the relationship between the breathing pattern variables with the variables of pulmonary function, respiratory muscle strength and respiration in patients after involvement by COVID-19. This is a observational and validation study, prospective with follow-up of respiratory function for 6 months, a subproject linked to the project already approved by the research ethics committee under opinion: 4.362.977/4.596.02. Data collection will be carried out in a single day and divided into a few steps that will take place at the cardiopulmonary physiotherapy laboratory located at the physiotherapy department of the Federal University of Pernambuco. The first step is to conduct an interview with the participants to collect clinical data and perform a physical examination. Subsequently, a multidimensional evaluation of respiratory function will be performed. Statistical analysis will be performed using the Statistical Package For Social Science (SPSS) software version 20.0 for Windows. The Kolmogorov-Smirnov test will be used to verify the type of distribution, regarding the normality of the variables, and the significance level adopted will be 95% (α <0.05) for all analyses. Finally, the data obtained will be presented in tables and/or graphs.


Description:

The sample will consist of volunteers with laboratory confirmed COVID-19 results who have SARS COV 2 variants tracked by the epidemiological surveillance of Caruaru-Pernambuco and will be recruited by coexistence in a non-probabilistic way. The sample study will be obtained through data provided by the municipal health department of the city of Caruaru-Pernambuco with a predicted sample of 131 people. In order to minimize sample losses, 10% will be added to the total sample, which corresponds to 144 participants. The software that can be used is known as GPower (version 3.13 for Windows) considering a statistical power (β) of 80% and a significance level (α) of 5%.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 10, 2023
Est. primary completion date December 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Older than 18 years; - Diagnosed with COVID-19; - After the period of home isolation or hospital discharge; - More than 40 days without the presence of symptoms associated with COVID-19; Exclusion Criteria: - Participants who are unable to perform the assessment tests or who present contraindications to the assessment of respiratory function; - Those patients who prove reinfection by the new Coronavirus; - Pregnant patients; - Refusal to sign the Free and Informed Consent Form (FICF)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Study will not have intervention
Study will not have intervention

Locations

Country Name City State
Brazil Federal University of Pernambuco Department of Physiotherapy Recife PE

Sponsors (3)

Lead Sponsor Collaborator
Shirley Lima Campos Conselho Nacional de Desenvolvimento Científico e Tecnológico, Universidade Federal de Pernambuco

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other Six-minute walk test Evaluation of functional capacity, through submaximal effort, through data obtained during a six-minute walk. The pre-test and post-test variables were measured:
BORG scale (scale from 0 to 10)
Perceived Effort (scale from 6 to 20)
Peripheral Oxygen Saturation (%)
Heart rate (measured in beats per minute)
Respiratory Rate (measured by breaths per minute)
Blood Pressure (mmHg)
Distance Traveled (measured in meters)
Expected Distance (%)
"Until the Completion of the Study, On Average 1 Year"
Other Palmar Grip Strength Assessment of handgrip strength through the dynamometry, measuring grip strength in a total of three repetitions, taking into account the greatest strength obtained in kilograms (kg/f) "Until the Completion of the Study, On Average 1 Year"
Primary Breathing pattern diagnosis The algorithm of the "Respiratory Diagnostic Assistant" device relates the variables respiratory rate, tidal volume, minute volume, inspiratory flow, expiratory flow, relationship between inspiratory and expiratory times, providing classification of breathing pattern during rest breathing. The "Respiratory Diagnosis Assistant" algorithm provides through graphs allowing the classification of the diagnosis in normal or altered.
Normal breathing pattern described in frequency of cases. It is defined no changes by the algorithm of the "Respiratory Diagnostic Assistant".
Altered breathing pattern described in frequency of cases. It is defined by changing the breathing pattern variables captured by the flow sensor of the "Respiratory Diagnostic Assistant" device during breathing at rest.
"Until the Completion of the Study, On Average 1 Year"
Primary Breathing pattern variables The algorithm of the "Respiratory Diagnostic Assistant" device relates the variables respiratory rate, tidal volume, minute volume, inspiratory flow, expiratory flow, relationship between inspiratory and expiratory times.
The variables of the breathing pattern will also be quantitatively evaluated::
Respiratory rate in incursion per minute
Tidal volume (measured in liters)
Minute volume (measured in liters);
Inspiratory flow (measured in liters);
Expiratory flow (measured in liters);
Ti/Ttotal, (measured in segunds)
I:E , relationship between inspiratory and expiratory times
Volume vs time;
Flow vs time.
"Until the Completion of the Study, On Average 1 Year"
Secondary Lung Function Lung function tests are usually performed with computerized systems that analyze the data and provide immediate results.
The spirometer associates variables capable of tracing a functional diagnosis of the respiratory system:
Forced vital capacity (FVC) (measured in liters);
Forced expiratory volume in 1 second - (FEV1) (measured in liters);
Relationship between forced vital capacity (FVC) and
Forced expiratory volume in 1 second - (FEV1);
Functional Diagnosis:
Normal
Obstructive ventilatory disorder (mild, moderate or severe)
Restrictive ventilatory disorder (mild, moderate or severe)
Mixed ventilatory disorder (with detection of obstructive and restrictive abnormality)
"Until the Completion of the Study, On Average 1 Year"
Secondary Assessment of lung volumes and capacities by ventilometry Non-invasive analogue assessment of lung volumes and capacities, easy to understand, with quantitative variables
Respiratory rate (RR) (measured in incursion per minute) Minute volume (MV), (measured in liters) Tidal volume (TV), (measured in liters) Inspiratory capacity (IC) (measured in liters) Vital capacity (CL) (measured in liters)
"Until the Completion of the Study, On Average 1 Year"
Secondary Maximum inspiratory pressure (Manuvacuometry) Manuvacuometry: Non-invasive measurement of inspiratory muscle pressure.
Maximum inspiratory pressure (MIP measured in cmH2O)
Maximum predicted inspiratory pressure (MIP predicted %)
"Until the Completion of the Study, On Average 1 Year"
Secondary Maximum expiratory pressure (Manuvacuometry) Manuvacuometry: Non-invasive measurement of inspiratory muscle pressure.
Maximum expiratory pressure (MEP - cmH2O)
Maximum predicted expiratory pressure (MEP predicted %)
"Until the Completion of the Study, On Average 1 Year"
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3